Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other brokerages have also commented on NBRV. Wedbush reiterated an “outperform” rating and set a $17.00 price objective on shares of Nabriva Therapeutics AG in a report on Tuesday, August 9th. HC Wainwright assumed coverage on Nabriva Therapeutics AG in a report on Thursday, September 8th. They set a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $15.38.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 6.84 on Wednesday. The company’s market cap is $145.40 million. Nabriva Therapeutics AG has a 12-month low of $6.58 and a 12-month high of $10.69. The firm’s 50-day moving average price is $7.43 and its 200 day moving average price is $7.87.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its earnings results on Tuesday, August 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.25) by $5.75. On average, analysts predict that Nabriva Therapeutics AG will post ($1.93) earnings per share for the current year.
A number of institutional investors have recently modified their holdings of the company. Vivo Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the first quarter worth about $28,239,000. Jackson Park Capital LLC purchased a new position in shares of Nabriva Therapeutics AG during the second quarter worth about $195,000. Finally, Opaleye Management Inc. raised its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares during the period. Institutional investors own 63.05% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.